» Articles » PMID: 189724

Fluphenazine Decanoate, Fluphenazine Hydrochloride Given Orally, and Placebo in Remitted Schizophrenics. I. Relapse Rates After One Year

Overview
Specialty Psychiatry
Date 1977 Jan 1
PMID 189724
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

In a simple remitted, nonpsychotic schizophrenics, the relapse rate within one year was significantly higher for those patients taking placebo as opposed to those taking fluphenazine hydrochloride orally or fluphenazine decanoate. There were no differences in relapse rates between the two active drugs, but there were significantly more terminations due to toxicity from fluphenazine decanoate than from pluphenazine given orally, entirely due to the fact that in 35% of patients receiving fluphenazine decanoate, severe akinesia developed.

Citing Articles

Antipsychotic Maintenance Treatment for Patients With Schizophrenia: The Need for Placebo-Controlled Trials and The Risk of Paradigm Shifts.

Lawrence R Schizophr Bull Open. 2024; 3(1):sgac058.

PMID: 39144771 PMC: 11205875. DOI: 10.1093/schizbullopen/sgac058.


Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study.

Kaur R, Sidana A, Malhotra N, Tyagi S Indian J Psychiatry. 2023; 65(4):404-411.

PMID: 37325092 PMC: 10263095. DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_389_22.


The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia.

Milz R, Benson C, Knight K, Antunes J, Najarian D, Lopez Rengel P Neuropsychiatr Dis Treat. 2023; 19:531-545.

PMID: 36915909 PMC: 10008005. DOI: 10.2147/NDT.S395383.


Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.

Lian L, Kim D, Procyshyn R, Cazares D, Honer W, Barr A PLoS One. 2022; 17(4):e0267808.

PMID: 35486616 PMC: 9053823. DOI: 10.1371/journal.pone.0267808.


Maintenance treatment with antipsychotic drugs for schizophrenia.

Ceraso A, Lin J, Schneider-Thoma J, Siafis S, Tardy M, Komossa K Cochrane Database Syst Rev. 2020; 8:CD008016.

PMID: 32840872 PMC: 9702459. DOI: 10.1002/14651858.CD008016.pub3.